Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
Andrew X. Zhu, RS Finn, Peter R. Galle, Josep M. Llovet, Jan Blanc, Takuji Okusaka, Ian Chau, Paolo Abada, Yanzhi Hsu, Masatoshi Kudo (2018). Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH). Annals of Oncology, 29, pp. v122-v122, DOI: 10.1093/annonc/mdy208.
